Cabaletta Bio, Inc.

Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
www.cabalettabio.com

Market Cap $59.41M
PE -1
Debt -
Cash $163.96M
EV -
FCF -$90.43M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$115.86M
EBIT	-$125.14M
ROE	-76%
ROA	-68%
FCF	-$90.43M
Equity	$152.34M
Growth Stability	1
PE	-0.51
PB	0.39
P/FCF	-0.66
Price/Cash	2.76
Equity CAGR	10%
Earnings Growth YoY	56%

Earnings Growth QoQ	6%
Equity CAGR 5Y	13%
Equity CAGR 3Y	36%
Market Cap	$59.41M
Assets	$185.05M
Cash	$163.96M
Shares Outstanding	49.51M
Working Capital	139.59M
Current Ratio	6.15
Shares Growth 3y	-11%
Equity Growth QoQ	-13%
Equity Growth YoY	-36%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAAR, T cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CAAR T cell product candidate was designed based on the clinically validated and commercially approved Chimeric Antigen Receptor, or CAR, T cell technology that is marketed for the treatment of B cell cancers.

SEC Filings

Direct access to Cabaletta Bio, Inc. (CABA) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Cabaletta Bio, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Cabaletta Bio, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Cabaletta Bio, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Cabaletta Bio, Inc..

Years

Calculation mode

= -$904M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$90M	-$90M	-$90M	-$90M	-$90M	-$90M	-$90M	-$90M	-$90M	-$90M	-$90M	-$904M
DCF		-$82M	-$75M	-$68M	-$62M	-$56M	-$51M	-$46M	-$42M	-$38M	-$35M	-$349M
Value	-$904M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Net Margins	-	-	-	-	-	-	-	-
ROA	-	-13%	-29%	-37%	-46%	-29%	-68%	-68%
ROE	-	-16%	-30%	-39%	-51%	-29%	-76%	-76%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Debt over FCF	-	-	-	-	-	-	-	-
Debt over Equity	-	-	-	-	-	-	-	-
Growth Stability	-	-	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	CAGR 5Y
Revenue YoY growth	-	-	-	-	-	-	-	-
Earnings YoY growth	-	83%	50%	39%	14%	28%	71%	-
Equity YoY growth	-	-1K%	-21%	8%	-11%	126%	-36%	13%
FCF YoY growth	-	-	64%	29%	38%	11%	67%	-